3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of Trypanosoma cruzi.
Drug design strategies based on Comparative Molecular Field Analysis (CoMFA) have been used to predict the activity of new compounds. The major advantage of this approach is that it permits the analysis of a large number of quantitative descriptors and uses chemometric methods such as partial least squares (PLS) to correlate changes in bioactivity with changes in chemical structure. Because it is often difficult to rationalize all variables affecting the binding affinity of compounds using CoMFA solely, the program GRID was used to describe ligands in terms of their molecular interaction fields, MIFs. The program VolSurf that is able to compress the relevant information present in 3D maps into a few descriptors can treat these GRID fields. The binding affinities of a new set of compounds consisting of 13 coumarins, for one of which the three-dimensional ligand-enzyme bound structure is known, were studied. A final model based on the mentioned programs was independently validated by synthesizing and testing new coumarin derivatives. By relying on our knowledge of the real physical data (i.e., combining crystallographic and binding affinity results), it is also shown that ligand-based design agrees with structure-based design. The compound with the highest binding affinity was the coumarin chalepin, isolated from Rutaceae species, with an IC50 value of 55.5 microM towards the enzyme glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) from glycosomes of the parasite Trypanosoma cruzi, the causative agent of Chagas' disease. The proposed models from GRID MIFs have revealed the importance of lipophilic interactions in modulating the inhibition, but without excluding the dependence on stereo-electronic properties as found from CoMFA fields.
Menezes
Irwin R A
IR
Núcleo de Estudos em Química Medicinal, NEQUIM, Chemistry Department, University of Minas Gerais, 31270-901, Belo Horizonte, MG, Brazil.
Lopes
Julio C D
JC
Montanari
Carlos A
CA
Oliva
Glaucius
G
Pavão
Fernando
F
Castilho
Marcelo S
MS
Vieira
Paulo C
PC
Pupo
Mônica T
MT
D000818:Animals; D001665:Binding Sites; D001688:Biological Products / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D014355:Chagas Disease / Q000628:therapy; D003198:Computer Simulation; D003374:Coumarins / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D018360:Crystallography, X-Ray; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011564:Furocoumarins / Q000737:chemistry / Q000378:metabolism; D024581:Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D006860:Hydrogen Bonding; D057927:Hydrophobic and Hydrophilic Interactions; D021621:Imaging, Three-Dimensional; D016018:Least-Squares Analysis; D008830:Microbodies / Q000201:enzymology; D008956:Models, Chemical; D008958:Models, Molecular; D008968:Molecular Conformation; D015394:Molecular Structure; D009243:NAD / Q000037:antagonists & inhibitors; D011485:Protein Binding; D021281:Quantitative Structure-Activity Relationship; D055672:Static Electricity; D013816:Thermodynamics; D014349:Trypanosoma cruzi / Q000201:enzymology*; D014867:Water / Q000737:chemistry
D001688:Biological Products; D003374:Coumarins; D004791:Enzyme Inhibitors; D011564:Furocoumarins; D014867:Water; D009243:NAD; C031533:chalepin; D024581:Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)